PDS Biotechnology (PDSB) to Release Earnings on Thursday

PDS Biotechnology (NASDAQ:PDSB) is set to announce its earnings results before the market opens on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.08. During the same period in the previous year, the firm posted ($0.37) EPS. On average, analysts expect PDS Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PDS Biotechnology Price Performance

NASDAQ:PDSB opened at $3.23 on Thursday. PDS Biotechnology has a 12-month low of $2.53 and a 12-month high of $6.85. The firm has a market cap of $118.93 million, a price-to-earnings ratio of -2.65 and a beta of 1.93. The company’s 50-day moving average is $3.25 and its two-hundred day moving average is $3.28. The company has a current ratio of 3.84, a quick ratio of 3.84 and a debt-to-equity ratio of 0.45.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $21.00 price objective on shares of PDS Biotechnology in a report on Thursday, October 24th. Alliance Global Partners raised PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. Finally, StockNews.com upgraded PDS Biotechnology from a “sell” rating to a “hold” rating in a report on Friday, November 1st. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $14.25.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.